UY34901A - ?monohidrato cristalino, procedimiento para su preparacion ysu utilizacion para la preparacion de un medicamento?. - Google Patents

?monohidrato cristalino, procedimiento para su preparacion ysu utilizacion para la preparacion de un medicamento?.

Info

Publication number
UY34901A
UY34901A UY34901A UY34901A UY34901A UY 34901 A UY34901 A UY 34901A UY 34901 A UY34901 A UY 34901A UY 34901 A UY34901 A UY 34901A UY 34901 A UY34901 A UY 34901A
Authority
UY
Uruguay
Prior art keywords
preparation
procedure
crystalline
monohidrate
medicinal product
Prior art date
Application number
UY34901A
Other languages
English (en)
Inventor
Dr Rolf Banholzer
Dr Peter Sieger
Dr Christian Kulinna
Dr Michael Trunk
Graulich Manfred
Specht Peter
Meissner Helmut
Mathes Andreas
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7659568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34901(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of UY34901A publication Critical patent/UY34901A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

?El invento se refiere a un monohidrato cristalino de bromuro de (1a,2ß, 4ß, 5a,7ß).7-[(hidroxi-di-2tienil-acetil)oxi]-9,9-dimetil-3oxa-9-azonia-triciclo[3.3.1.0,]nonano, a un procedimiento para su preparación, así como a su utilización para la preparación de un medicamento, particularmente para la preparación de un medicamento con efecto anticolinérgico?. NOTA EN [3.3.1.02,4] 3.3.1.0 ES A LA 2.4 (POTENCIA)
UY34901A 2000-10-12 2013-07-11 ?monohidrato cristalino, procedimiento para su preparacion ysu utilizacion para la preparacion de un medicamento?. UY34901A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10050621 2000-10-12

Publications (1)

Publication Number Publication Date
UY34901A true UY34901A (es) 2015-02-27

Family

ID=7659568

Family Applications (2)

Application Number Title Priority Date Filing Date
UY26962A UY26962A1 (es) 2000-10-12 2001-10-10 Monohidrato cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento
UY34901A UY34901A (es) 2000-10-12 2013-07-11 ?monohidrato cristalino, procedimiento para su preparacion ysu utilizacion para la preparacion de un medicamento?.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY26962A UY26962A1 (es) 2000-10-12 2001-10-10 Monohidrato cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento

Country Status (47)

Country Link
EP (2) EP1326862B1 (es)
JP (1) JP3764422B2 (es)
KR (1) KR100823860B1 (es)
CN (2) CN100519558C (es)
AP (1) AP1572A (es)
AR (2) AR034389A1 (es)
AT (1) ATE276253T1 (es)
AU (2) AU2002214996B2 (es)
BG (1) BG66161B1 (es)
BR (1) BR0114584A (es)
CA (1) CA2425539C (es)
CR (1) CR6938A (es)
CZ (1) CZ301841B6 (es)
DE (1) DE50103666D1 (es)
DK (1) DK1326862T3 (es)
DZ (1) DZ3478A1 (es)
EA (1) EA004381B1 (es)
EC (1) ECSP034540A (es)
EE (1) EE04567B1 (es)
EG (1) EG24142A (es)
ES (1) ES2228965T3 (es)
GE (1) GEP20063905B (es)
HK (2) HK1060567A1 (es)
HR (1) HRP20030276B1 (es)
HU (1) HU226830B1 (es)
IL (2) IL155335A0 (es)
IS (1) IS2339B (es)
MA (1) MA25842A1 (es)
ME (2) ME00243B (es)
MX (1) MXPA03003221A (es)
MY (1) MY126931A (es)
NO (1) NO328465B1 (es)
NZ (1) NZ525733A (es)
OA (1) OA12403A (es)
PE (1) PE20020422A1 (es)
PL (1) PL207870B1 (es)
PT (1) PT1326862E (es)
RS (1) RS50218B (es)
SA (1) SA01220412B1 (es)
SI (1) SI1326862T1 (es)
SK (1) SK287009B6 (es)
TR (1) TR200402579T4 (es)
TW (1) TW589313B (es)
UA (1) UA74215C2 (es)
UY (2) UY26962A1 (es)
WO (1) WO2002030928A1 (es)
ZA (1) ZA200302500B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608055B2 (en) 2001-06-22 2003-08-19 Boehringer Ingelheim Pharma Kg Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
BR0210537A (pt) * 2001-06-22 2004-06-22 Boehringer Ingelheim Pharma Anticolinérgico cristalino, processo para a sua preparação e sua aplicação para a preparação de um medicamento
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
DE10214263A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
US7311894B2 (en) 2002-03-28 2007-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations containing an anticholinergic
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
DE10317461A1 (de) 2003-04-16 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Radioaktiv markierte Mikropartikel, Verfahren zu deren Herstellung und deren Verwendung
AU2004285684B2 (en) * 2003-11-03 2011-07-14 Boehringer Ingelheim International Gmbh Novel crystalline anhydride with anticholinergic effect
UY28589A1 (es) * 2003-11-03 2005-06-30 Boehringer Ingelheim Int Nuevas sales de tiotropio, procedimientos para su preparación , así como formulaciones medicamentosas que las contienen
SG137859A1 (en) 2003-11-03 2007-12-28 Boehringer Ingelheim Int Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
US7968717B2 (en) 2003-11-03 2011-06-28 Boehringer Ingelhein International Gmbh Crystalline anhydrate with anticholinergic efficacy
DE102004016179A1 (de) * 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von proliferativen Prozessen
BRPI0510080B8 (pt) 2004-04-22 2021-05-25 Boehringer Ingelheim Int combinação farmacêutica e seu uso
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004024454A1 (de) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE602004020337D1 (de) 2004-08-11 2009-05-14 Boehringer Ingelheim Pharma Anticholinergika enthaltende Arzneimittel zur Behandlung von Krankheiten der ableitenden Harnwege
US20060079544A1 (en) * 2004-08-13 2006-04-13 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
DE102004048389A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Modifizierung von Oberflächen von Laktose als Hilfsstoff zur Verwendung für Pulverinhalativa
JP5566576B2 (ja) * 2004-10-21 2014-08-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 吸入器用ブリスタ
JP2008532973A (ja) * 2005-03-09 2008-08-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とｐｄｅ５−阻害剤に基づく新規な医薬組成物
KR20080007645A (ko) 2005-04-28 2008-01-22 베링거 인겔하임 인터내셔날 게엠베하 염증성 질환 치료용 신규 화합물
JP5227790B2 (ja) 2005-05-02 2013-07-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規結晶性臭化チオトロピウム
JP2008540367A (ja) * 2005-05-02 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規結晶性臭化チオトロピウム
EP1896026B1 (en) * 2005-06-15 2013-10-09 Boehringer Ingelheim International GmbH Process for preparing tiotropium salts, tiotropium salts as such and pharmaceutical compositions thereof
DE102005030733A1 (de) 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
NZ566399A (en) * 2005-08-06 2011-07-29 Boehringer Ingelheim Int Use of tiotropium salts in the treatment of severe persistant asthma
RU2412176C2 (ru) 2005-08-15 2011-02-20 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения бетамиметиков
TWI396541B (zh) 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
US7423146B2 (en) 2005-11-09 2008-09-09 Boehringer Ingelheim International Gmbh Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones
DE102005059602A1 (de) * 2005-12-14 2007-06-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mikronisierung
CN102731494A (zh) 2005-12-19 2012-10-17 西科尔公司 噻托溴铵的新形式及其制备方法
EP1966196A2 (en) * 2005-12-19 2008-09-10 Sicor, Inc. Pure and stable tiotropium bromide
ES2362306T3 (es) * 2006-01-04 2011-07-01 Boehringer Ingelheim International Gmbh Uso de sales de tiotropio en el tratamiento de asma persistente moderada.
EP2060575A1 (de) 2006-04-19 2009-05-20 Boehringer Ingelheim International GmbH Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
US20080051582A1 (en) 2006-07-10 2008-02-28 Sicor Inc. Process for the preparation of tiotropium bromide
CA2660186A1 (en) 2006-08-07 2008-02-14 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of respiratory diseases
UY30550A1 (es) 2006-08-22 2008-03-31 Boehringer Ingelheim Int Nuevos beta-agonistas enantioméricamente puros, procedimientos para su preparacion y su uso como medicamentos
EP1923393A1 (en) * 2006-11-17 2008-05-21 Boehringer Ingelheim Pharma GmbH & Co. KG Crystalline form of tiotropium bromide and urea
EP1925295A1 (de) 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stabile Pulverformulierung enthaltend ein Anticholinergikum
GB0716026D0 (en) * 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
MY153979A (en) 2007-10-19 2015-04-30 Boehringer Ingelheim Int Substituted piperidino-dihydrothienopyrimidine
EP2093219A1 (de) 2008-02-22 2009-08-26 Boehringer Ingelheim International Gmbh Kristalline, enantiomerenreine Salzform eines Betamimetikums und dessen Verwendung als Arzneimittel
US20100272811A1 (en) * 2008-07-23 2010-10-28 Alkermes,Inc. Complex of trospium and pharmaceutical compositions thereof
DK2379525T3 (en) 2008-12-19 2015-10-19 Boehringer Ingelheim Int Cyclic pyrimidin-4-carboxamides, as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
EP2201934A1 (en) 2008-12-23 2010-06-30 CHIESI FARMACEUTICI S.p.A. Tiotropium aerosol formulation products with improved chemical stability
EP2403851B1 (en) 2009-03-06 2015-06-17 Mahmut Bilgic New crystalline forms of tiotropium bromide
WO2011015883A1 (en) 2009-08-07 2011-02-10 Generics [Uk] Limited Dichloromethane solvate of tiotropium bromide and its use
NZ624602A (en) 2009-08-07 2015-11-27 Generics Uk Ltd Anhydrate of tiotropium bromide
EP2513086B1 (en) 2009-12-17 2015-04-29 Boehringer Ingelheim International GmbH Novel antagonists for ccr2 and uses thereof
DK2513093T3 (da) 2009-12-17 2014-09-29 Boehringer Ingelheim Int Nye CCR2 receptor antagonister og anvendelser deraf
MX2012008533A (es) 2010-01-29 2012-08-31 Boehringer Ingelheim Int Naftiridinas sustituidas y su uso como inhibidores de syk quinasa.
US8877745B2 (en) 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8946218B2 (en) 2010-05-12 2015-02-03 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2571870B1 (en) 2010-05-17 2015-01-21 Boehringer Ingelheim International GmbH Ccr2 antagonists and uses thereof
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
WO2012101013A1 (en) 2011-01-28 2012-08-02 Boehringer Ingelheim International Gmbh Substituted pyridinyl-pyrimidines and their use as medicaments
TR201102068A2 (tr) 2011-03-03 2012-09-21 Bi̇lgi̇ç Mahmut Tiotropyum bromür içeren kristal maddeler
JP5786257B2 (ja) 2011-06-16 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の選択的ｃｃｒ２拮抗薬
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
CA2843022C (en) 2011-07-26 2019-09-24 Boehringer Ingelheim International Gmbh Substituted quinolines and their use as medicaments
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
CZ304368B6 (cs) * 2011-11-28 2014-04-02 Zentiva, K.S. Směsný solvát tiotropium bromidu a způsob jeho přípravy
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
US9096579B2 (en) 2012-04-20 2015-08-04 Boehringer Ingelheim International Gmbh Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
RS55919B1 (sr) 2012-11-05 2017-09-29 Zentiva As Stabilizacija solvata tiotropijuma
EP2913332A1 (en) * 2014-02-27 2015-09-02 Euticals S.P.A. Crystalline form of tiotropium bromide with lactose
PT3119772T (pt) 2014-03-19 2019-09-05 Boehringer Ingelheim Int Inibidores de syk heteroarilo
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
RU2567539C1 (ru) * 2015-02-04 2015-11-10 Индивидуальный предприниматель Михайлов Олег Ростиславович КРИСТАЛЛИЧЕСКАЯ γ-МОДИФИКАЦИЯ (1α,2β,4β,5α,7β-7)-[(ГИДРОКСИДИ-2-ТИЕНИЛАЦЕТИЛ)ОКСИ]-9,9-ДИМЕТИЛ-3-ОКСА-9-АЗОНИАТРИЦИКЛО[3.3.1.02,4]НОНАН БРОМИДА МОНОГИДРАТА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЁ ОСНОВЕ
WO2017138896A1 (en) 2016-02-11 2017-08-17 Sima Patent Ve Lisanslama Hizmetleri Ltd. Şti Crystalline form of tiotropium bromide anhydrate
WO2018084817A2 (en) * 2016-11-04 2018-05-11 Si̇ma Patent Ve Li̇sanslama Hi̇zmetleri̇ Ltd. Şti̇ A new form of active agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
AU680227B2 (en) * 1992-12-09 1997-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Stabilized medicinal aerosol solution formulations
DE19834506A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Transmucosales therapeutisches System zur Anwendung von Sildenafil
US6475467B1 (en) * 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations

Also Published As

Publication number Publication date
TR200402579T4 (tr) 2004-12-21
PT1326862E (pt) 2004-11-30
DE50103666D1 (de) 2004-10-21
BG66161B1 (bg) 2011-09-30
IS2339B (is) 2008-02-15
HRP20030276B1 (en) 2006-02-28
AR068527A2 (es) 2009-11-18
PE20020422A1 (es) 2002-06-28
UY26962A1 (es) 2002-06-20
EP1326862A1 (de) 2003-07-16
HUP0301022A2 (hu) 2003-10-28
CN1733761A (zh) 2006-02-15
SK287009B6 (sk) 2009-09-07
AP1572A (en) 2006-02-13
HRP20030276A2 (en) 2005-02-28
DK1326862T3 (da) 2004-11-22
NO20031694D0 (no) 2003-04-11
YU27303A (sh) 2006-05-25
ME00243B (me) 2011-05-10
AR034389A1 (es) 2004-02-25
IL155335A0 (en) 2003-11-23
HU226830B1 (en) 2009-11-30
IS6772A (is) 2003-04-09
ECSP034540A (es) 2003-07-25
GEP20063905B (en) 2006-08-25
HK1060567A1 (en) 2004-08-13
WO2002030928A1 (de) 2002-04-18
AU2002214996B2 (en) 2007-03-15
MY126931A (en) 2006-10-31
CA2425539C (en) 2007-04-03
CA2425539A1 (en) 2003-04-11
JP2004526668A (ja) 2004-09-02
EA004381B1 (ru) 2004-04-29
HUP0301022A3 (en) 2005-12-28
CN1469877A (zh) 2004-01-21
MEP40008A (en) 2011-02-10
CZ301841B6 (cs) 2010-07-07
EG24142A (en) 2008-08-06
IL155335A (en) 2009-02-11
RS50218B (sr) 2009-07-15
EA200300457A1 (ru) 2003-10-30
OA12403A (en) 2006-04-18
NO20031694L (no) 2003-04-11
CR6938A (es) 2004-10-28
MXPA03003221A (es) 2004-12-03
EP1468998A1 (de) 2004-10-20
HK1086557A1 (en) 2006-09-22
NZ525733A (en) 2005-01-28
DZ3478A1 (fr) 2002-04-18
SK4362003A3 (en) 2003-08-05
NO328465B1 (no) 2010-02-22
PL207870B1 (pl) 2011-02-28
KR20030042008A (ko) 2003-05-27
PL366041A1 (en) 2005-01-24
BR0114584A (pt) 2003-08-26
BG107687A (bg) 2003-09-30
JP3764422B2 (ja) 2006-04-05
CN100519558C (zh) 2009-07-29
EP1326862B1 (de) 2004-09-15
UA74215C2 (uk) 2005-11-15
SA01220412B1 (ar) 2006-11-05
KR100823860B1 (ko) 2008-04-21
ZA200302500B (en) 2004-04-22
ES2228965T3 (es) 2005-04-16
SI1326862T1 (en) 2005-02-28
MA25842A1 (fr) 2003-07-01
CN1221549C (zh) 2005-10-05
EE200300171A (et) 2003-06-16
AP2003002775A0 (en) 2003-03-31
AU1499602A (en) 2002-04-22
TW589313B (en) 2004-06-01
ATE276253T1 (de) 2004-10-15
EE04567B1 (et) 2005-12-15

Similar Documents

Publication Publication Date Title
UY34901A (es) ?monohidrato cristalino, procedimiento para su preparacion ysu utilizacion para la preparacion de un medicamento?.
UY27342A1 (es) Agente anticolinérgico cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento
UY27725A1 (es) Material micronizado cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento.
AR023972A1 (es) Composiciones de medicamentos a base de compuestos anticolinergicamente activos y beta-mimeticos
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
ZA200305412B (en) 4-fluoro-N-indan-2-yl benzamide and its use as pharmaceutical.
HN1999000124A (es) Derivados de pirazol substituido.
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
HN2001000019A (es) Derivados de nicotinamida benzocondensada heterociclico utiles como inhibidores selectivos de las isozimas pde4.
AR034213A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv
CO4340688A1 (es) Derivados de quinazolina y procedimientos de uso de los mismos, como agentes contra el cancer, en los mamiferos.
ES2179351T3 (es) Amidas acidas de piridil alqueno y piridil alquino como citoestaticos e inmunosupresores.
AR109263A2 (es) Composición que comprende moxidectina
AR040130A1 (es) Esteres de etonogestrel, su uso como anticopceptivo y para el tratamiento de desordenes ginecologicos
ES2160680T3 (es) Utilizacion de un antagonista de sustancia p en una composicion farmaceutica.
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
ES2253378T3 (es) Extractos de espermatofitos con actividad antineoplasica.
PA8581701A1 (es) Derivados de indolilo
WO2003057241A1 (fr) Agents favorisant la proliferation et/ou la differenciation de cellules souches hematopoietiques et/ou de precurseurs hematopoietiques
AR050574A1 (es) Uso de un compuesto para estimulacion del crecimiento de pelo
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
ES2193424T3 (es) Aminas triciclicas farmaceuticamente activas.
PA8509601A1 (es) &#34;PIRAZOLO [4,3,e] DIAZEPINAS SUSTITUIDAS NOVEDOSAS, COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN, SU USO COMO PRODUCTOS MEDICINALES Y PROCESOS PARA PREPARARLAS
FR2820144B1 (fr) Postes de securite microbiologique utilisables en assistance medicale a la procreation
BR0110989A (pt) Derivados de 2-aminotetralina opticamente ativos, os processos para a preparação deles e uso terapêutico de composições farmacêuticas que os contêm

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210602